Alembic Pharma net profit rises 48 percent to Rs 180 crore in Q3

Its net sales increased 8 per cent to Rs 1,631 crore for the third quarter from Rs 1,509 crore in the year ago period, Alembic Pharma said in a statement.

Published On 2024-02-06 06:06 GMT   |   Update On 2024-03-22 08:53 GMT
Advertisement

Vadodara: Alembic Pharmaceuticals has reported a 48 per cent increase in its consolidated net profit to Rs 180 crore for the third quarter ended December 2023, due to robust sales across domestic and export markets.

The drug maker had reported a net profit of Rs 122 crore in the October-December period of the last fiscal.

Its net sales increased 8 per cent to Rs 1,631 crore for the third quarter from Rs 1,509 crore in the year-ago period, Alembic Pharmaceuticals said in a statement.

Advertisement

"The India branded business was underpinned by a continued incremental improvement in core operations. The speciality and animal health segments continued its strong performance; whereas the acute performance was relatively satisfactory despite challenging market conditions. The Ex US generics grew 32% in the quarter, whereas the US returned to a 9% growth on the back of 11 launches and 7 approvals," Alembic Pharmaceuticals MD Shaunak Amin said.

Medical Dialogues team had earlier reported that the second-quarter profit of India's Alembic Pharma was roughly in line with estimates, as higher sales in its domestic and overseas markets offset a jump in expenses.

Headquartered in Vadodara, Gujarat, Alembic Pharmaceuticals Limited is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. The company was founded in 1907. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.

Read also: Alembic Pharma Gets CDSCO Panel Nod to Study FDC Carbidopa, Levodopa ER Capsule for export purpose only

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News